CTOs on the Move

Aurora Spine

www.auroraspine.us

 
Aurora Spine Corporation focuses on the development and distribution of spinal implant products for relieving back pain, and preserving spinal bone structure and anatomy in the United States. The company intends to provide interspinous process lumbar fusion devices for patients suffering from degenerative disc disease whose pain has not been eliminated by non-surgical treatment methods; polyether ether ketone interbody cages for use in spinal fusion procedures; and cervical and lumbar devices. It also plans to develop installation tools for surgeons. The company was incorporated in 2013 and is headquartered in Toronto, Canada.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.auroraspine.us
  • 1920 Palomar Point Way
    Carlsbad, CA USA 92008-5577
  • Phone: 760.424.2004

Executives

Name Title Contact Details

Similar Companies

Stinger Medical

Stinger Medical is a Murfreesboro, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DataMetrix

DataMetrix is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Salt Lake City, UT. To find more information about DataMetrix, please visit www.data-metrix.com

Upstream Rehabilitation

National Family of Local Therapy Providers providing exceptional care & remarkable experiences. #UpstreamFamily Learn more: https://t.co/fpCrnr3vfc…

Pediatric Services of America (PSA Healthcare)

Pediatric Services of America, Inc (PSA Healthcare) is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Pediatric Services of America, Inc (PSA Healthcare) is based in Norcross, GA. You can find more information on Pediatric Services of America, Inc (PSA Healthcare) at www.psahealthcare.com

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.